PTO/SB/21 (02-04)
Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE vork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number. **Application Number** 10/816,698 Filing Date TRANSMITTAL April 2, 2004 First Named Inventor **FORM** Mien-Chie Hung Art Unit N/A (to be used for all correspondence after initial filing) **Examiner Name** Not Yet Assigned Attorney Docket Number Total Number of Pages in This Submission 5 AH-UTSC:791US ENCLOSURES (Check all that apply) After Allowance communication Fee Transmittal Form Drawing(s) to Technology Center (TC) Appeal Communication to Board of Fee Attached Licensing-related Papers Appeals and Interferences Appeal Communication to TC Amendment/Reply Petition (Appeal Notice, Brief, Reply Brief) Petition to Convert to a After Final Proprietary Information Provisional Application Power of Attorney, Revocation Affidavits/declaration(s) Status Letter Change of Correspondence Address Other Enclosure(s) (please Extension of Time Request Terminal Disclaimer Identify below): IDS (Citation) by Applicant **Express Abandonment Request** Request for Refund IDS References Cited (8) Postcard x Information Disclosure Statement CD, Number of CD(s) Certified Copy of Priority Document(s) Remarks Response to Missing Parts/ Incomplete Application Response to Missing Parts under 37 CFR 1.52 or 1.53 SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT Firm FULBRIGHT & JAWORSKI L.L.P. Melissa L. Sistrunk - 45,579 Individual name meluse GA Signature Date July 16, 2004

_	
l	Transmittal
	I hereby certify that this correspondence is being deposited with the U.S. Postal Service as Express Mail, Airbill No. ER 509324736US, in an envelope addressed to: Commissioner for Patents, P.O. Boy 1450, Alexandria, VA 22313-1450, on the date shown below.
l	Dated: July 16, 2004 Signature: Moriea L. Thomas)

I hereby certify that this correspondence is being deposited with the U.S. Postal Service as Express Mail, Airbill No. ER 509324736US, in an envelope addressed to: Commissioner for Patents, P.O. Box 1450 Alexandria, VA 22313-1450, on the date shown below

d: July 16, 2004

JUL 1 6 2004

unes Signature:

(Monica L. Thomas)

Docket No.: AH-UTSC:791US (PATENT)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

e Patent Application of: Mien-Chie Hung et al.

Application No.: 10/816,698

Filed: April 2, 2004 Art Unit: N/A

For: ANTITUMOR EFFECT OF MUTANT BIK Examiner: Not Yet Assigned

INFORMATION DISCLOSURE STATEMENT (IDS)

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Dear Sir:

Pursuant to 37 CFR 1.56, 1.97 and 1.98, the attention of the Patent and Trademark Office is hereby directed to the references listed on the attached PTO/SB/08. It is respectfully requested that the information be expressly considered during the prosecution of this application, and that the references be made of record therein and appear among the "References Cited" on any patent to issue therefrom.

This Information Disclosure Statement is filed more than three months after the U.S. filing date, but before the mailing date of the first Office Action on the merits.

I hereby certify that no item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application and, to my knowledge after making reasonable inquiry, no item of information contained in this Information Disclosure Statement was known to any individual designated in 37 CFR 1.56(c) more than three months prior to the filing of this Information Disclosure Statement.

A copy of each reference on the PTO/SB/08 is attached.

In accordance with 37 CFR 1.97(g), the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made or that no other material information as defined in 37 CFR 1.56(a) exists. In accordance with 37 CFR 1.97(h), the filing of this Information Disclosure statement shall not be construed to be an admission that any patent, publication or other information referred to therein is "prior art" for this invention unless specifically designated as such.

It is submitted that the Information Disclosure Statement is in compliance with 37 CFR 1.98 and the Examiner is respectfully requested to consider the listed references.

The Director is hereby authorized to charge any deficiency in the fees filed, asserted to be filed or which should have been filed herewith (or with any paper hereafter filed in this application by this firm) to our Deposit Account No. 06-2375, under Order No. AH-UTSC:791US. A duplicate copy of this paper is enclosed.

Dated: July 16, 2004

Respectfully submitted,

By Nelu Llf Melissa L. Sistrunk

Registration No.: 45,579

FULBRIGHT & JAWORSKI L.L.P.

1301 McKinney, Suite 5100 Houston, Texas 77010-3095

(713) 651-5151

(713) 651-5246 (Fax)

Attorney for Applicant

PTO/SB/08A (10-01)
Approved for use through 10/31/2002.OMB 0651-0031
U. S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Inder the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Sub	stitute for form 1449A/PTO			Complete if Known		
				Application Number	10/816,698	
IN.	VEORMATION	N DI	SCLOSURE	Filing Date	April 2, 2004	
S	TATEMENT I	BY A	APPLICANT	First Named Inventor	Mien-Chie Hung	
				Art Unit	N/A	
	(use as many sh	eets as	necessary)	Examiner Name	Not Yet Assigned	
Sheet	1	of	1	Attorney Docket Number	AH-UTSC:791US	

	U.S. PATENT DOCUMENTS				
Examiner Initials*	Cite No.1	Cité	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		60/559,111	04-02-2004	Hung, Mien-Chie, et al.	

FOREIGN PATENT DOCUMENTS							
Examiner Initials*	Cite No. ¹	Foreign Patent Document Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T°	

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant

¹Applicant's unique citation designation number (optional). ² See attached Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the application number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	CA	Bartke, T., et al.; p53 upregulates cFLIP, inhibits transcription of NF-kB-regulated genes and induces caspase-8-independent cell death in DLD-1 cells, Oncogene (2001) Vol. 20, pp. 571-580.	
	СВ	Zou, Yiyu, et al.; Systemtic tumor suppression by the proapoptotic gene bik1, Cancer Research (January 2002), Vol. 62, pp. 8-12.	
	СС	Daniel, Peter T. et al.; Expression of the death gene bik/Nbk promotes sensitivity to drug-induced apoptosis in corticosteroid-resistant t-cell lymphoma and prevents tumor growth in severe combined immunodeficient mice, Neoplasia (August 1999) Vol. 94, No. 3, pp. 1100-1107.	
	CD	Han, Jeonghoon, et al.; induction of apoptosis by human Nbk/Bik, a BH3-containing protein that interacts with E1B 19K, Molecular and Cellular Biology (October 1996), pp. 5857-5864.	
	CE	Panaretakis, Theocharis, et al.; Activation of bak, bax, and BH3-only proteins in the apoptotic response to doxorubicin, Journal of Bio. Chem. (November 2002), Vol. 277, No. 46, pp. 44317-44326.	
	CF	Friedman, Debbie, et al.; Ecteinascidin-743 inhibits activated but not constitutive transcription, Cancer Research, (June 2002) Vol. 62, pp. 3377-3381.	
	CG	Verma, Sulekha, et al.; Phosphorylation of the pro-apoptotic protein BIK, Journal of Bio. Chem., (February 2001) Vol. 276, No.7, pp. 4671-4676.	

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

	<u>_</u>			
25433831.1		· · · · · · · · · · · · · · · · · · ·	 Date	
Examiner			Considered	
Signature				

¹Applicant's unique citation designation number (optional). 2Applicant is to place a check mark here if English language Translation is attached.



Application No. (if known): 10/816,698

Attorney Docket No.: AH-UTSC:791US

Certificate of Express Mailing Under 37 CFR 1.10

I hereby certify that this correspondence is being deposited with the United States Postal Service as Express Mail, Airbill No. ER 509324736US in an envelope addressed to:

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

on July 16, 2004 Date

Signature

Monica L. Thomas

Typed or printed name of person signing Certificate

Note: Each paper must have its own certificate of mailing, or this certificate must identify each submitted paper.

IDS (Citation) by Applicant